Showing results (121-130 of 318) with videos related to

Sort By:
Pageof 32
Frontiers in Oncology|September 20, 2021
<i>EGFR</i> Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical OutcomesHaiyan Xu, Guangjian Yang, Weihua Li, et al.
Molecular Biotechnology|January 27, 2023
Optimization of piggyBac Transposon System Electrotransfection in Sheep FibroblastsDipeng Zhao, Jian Qin, Jie An, et al.
Journal of Environmental Sciences (China)|August 2, 2024
The role of sulfur cycle in new particle formation: Cycloaddition reaction of SO<sub>3</sub> to H<sub>2</sub>SHaijie Zhang, Wei Wang, Liang Fan, et al.
Frontiers in Microbiology|November 28, 2025
Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patientsJing Wang, Wei Su, Qin Chen, et al.
Thoracic Cancer|March 20, 2026
TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung AdenocarcinomaLige Wu, Zihua Zou, Yan Li, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam|December 23, 2021
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-AnalysisTongji Xie, Zihua Zou, Chengcheng Liu, et al.
Cancer Medicine|August 14, 2019
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world studyGuangjian Yang, Di Ma, Haiyan Xu, et al.
Thoracic Cancer|April 15, 2018
Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trialLu Yang, Sheng Yang, Yutao Liu, et al.
Targeted Oncology|May 25, 2019
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with OsimertinibYuxin Mu, Xuezhi Hao, Ke Yang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 24, 2016
Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center large-scale investigation of 1, 504 Chinese Han patientsLin Yang, Yun Ling, Lei Guo, et al.
Pageof 32